Invasive pneumococcal disease may be the first sign of undiagnosed blood cancers and antibody deficiencies in adults, a new study finds.
|Articles|September 9, 2021
Pharmacy Clinical Pearl of the Day: Pneumonia Vaccines
Author(s)Saro Arakelians, PharmD
Vaccines help prevent pneumococcal disease, which is any type of illness caused by Streptococcus pneumoniae bacteria.
Advertisement
Clinical Pearl of the Day: Pneumonia vaccines
- Vaccines help prevent
pneumococcal disease , which is any type of illness caused by Streptococcus pneumoniae bacteria.
Explanation:
- Types of pneumonia vaccines approved by the FDA:
- Pneumococcal conjugate vaccine or PCV13.
- Pneumococcal polysaccharide vaccine or PPSV23.
- Pneumococcal 20-valent Conjugate Vaccine or Prevnar 20.
- CDC recommends PCV13:
- For all children younger than 2 years of age and people 2 years of age and older with certain conditions.
- CDC recommends PRSV23:
- For all adults 65 years of age or older, people 2 through 64 years of age with certain medical conditions.
- For all adults 19 through 64 years of age who smoke cigarettes.
- Prevnar 20 is recommended for adults 18 years of age and older.
Reference:
Advertisement
Related to this article
A behavioral walking program matched supervised aerobic training for improving asthma control in a randomized trial of physically inactive adults.
Phase 2b data from EASD 2026 show the amylin-incretin combination also cut HbA1c by up to 2.9% in adults with obesity or overweight and type 2 diabetes.
American Pharmacists Month kicked off on October 1, honoring more than 700,000 pharmacy professionals and 250 years of caring for America's communities.
fMRI data show cagrilintide-semaglutide altered brain responses to high-calorie food cues; REIMAGINE analyses point to ectopic fat and bone effects.
A pharmacist-led collaborative drug therapy management program at NYC Health + Hospitals/Bellevue reported high patient satisfaction, and every surveyed patient said they felt respected and supported by their pharmacist.
A Novo Nordisk–funded claims analysis of adults with type 2 diabetes found an adjusted HR of 1.06 for MACE with switching, although the findings cannot show causation.
A new analysis finds a significant weight loss edge for tirzepatide under one estimand but not another; no head-to-head trial exists at these doses.
Advertisement
Advertisement
Trending on Pharmacy Times
1
EloraTZP Delivers Up to 23.3% Weight Loss in Adults With Obesity and T2D
2
Pharmacists Key to Lp(a) Counseling and Lipid Optimization
3
Why Lp(a) Testing Lagged Behind LDL Cholesterol Screening
4
What the 2025-2030 Dietary Guidelines Mean for Heart Health
5